Patients are now being identified earlier than ever, and new drugs approved by the FDA are prolonging their lives significantly.

Four years after getting the first drug approved by the FDA to treat rare disease hereditary ATTR amyloidosis, Alnylam has got the go-ahead for a second – Amvuttra – which has a simpler, more ...

DUBLIN--Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights ...

Net cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full year of 2025, respectively; quarter-end cash and restricted cash position ...

Actor Morgan Freeman speaks from the heart about ATTR-CM. Through a partnership with BridgeBio, the celebrated actor is ‘the ...

Cardiac amyloidosis is a progressive condition that affects the heart and other organs, but new FDA-approved drugs are prolonging the lives of those affected and early identification is now possible.

This news comes amid a push within value-based care to ensure high-cost medical interventions deliver meaningful improvements ...

If you’ve ever wondered about those little signs your heart might be trying to tell you, this one’s for all of us.We sat down with Dr. Henry Cheng — a cardiolo ...

It is noteworthy that reactive or secondary amyloidosis can occasionally occur in patients with other neoplasms (hepatocellular carcinoma, renal cell carcinoma, Castleman's disease, Hodgkin's disease, ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) ranks among the best innovative stocks to buy according to Wall Street analysts.

Although it is rare, cardiac amyloidosis is an important heart disease to pay attention to because its symptoms can be easy to overlook and often resemble those of other heart ...

Valentine’s Day is National Donor Day. It's a time to honor organ donors and the families who say yes in the midst of loss.